RT @FarahAllouch3: We all talk about the SPRINT findings that clearly demonstrate that intensive BP control leads to reductions in all-caus…
We all talk about the SPRINT findings that clearly demonstrate that intensive BP control leads to reductions in all-cause and CVD mortality, but we don't talk as much about what happened AFTER SPRINT. https://t.co/J3XnNqXJAO.
RT @JurgaTomek: Mortality benefit of intensive BP diminished after SPRINT trail ended. SBP ⬆️ from 133 mmHg to about 140 mmHg ~5 after tri…
RT @sarahkmels: @hswapnil @NephJC @Jithukurian6 @dani_nephron @TimAndersonMD @OttawaRenal Very great pre- #nephjc presentation here 👆 Dr. @…
RT @sarahkmels: @NephJC yes, agreed, exactly!, similarly, this post-SPRINT 2022 study via @JAMA_current by Dr. @adambress et al: https://t.…
@NephJC yes, agreed, exactly!, similarly, this post-SPRINT 2022 study via @JAMA_current by Dr. @adambress et al: https://t.co/n6934vN5nq #nephjc
RT @sarahkmels: @hswapnil @NephJC @Jithukurian6 @dani_nephron @TimAndersonMD @OttawaRenal Very great pre- #nephjc presentation here 👆 Dr. @…
@hswapnil @NephJC @Jithukurian6 @dani_nephron @TimAndersonMD @OttawaRenal Very great pre- #nephjc presentation here 👆 Dr. @TimAndersonMD makes a key point re: pt. selection, & am reminded of this classic 2022 post-SPRINT ref. via @JAMA_current by Dr. @
RT @TomPMarshall: Long term effects of intensive BP treatment TL:DR - the advantage of intensive treatment gradually disappeared https://t…
RT @TomPMarshall: Long term effects of intensive BP treatment TL:DR - the advantage of intensive treatment gradually disappeared https://t…
RT @TomPMarshall: Long term effects of intensive BP treatment TL:DR - the advantage of intensive treatment gradually disappeared https://t…
RT @TomPMarshall: Long term effects of intensive BP treatment TL:DR - the advantage of intensive treatment gradually disappeared https://t…
Long term effects of intensive BP treatment TL:DR - the advantage of intensive treatment gradually disappeared https://t.co/bgPzQANDjD
Consistent long term management of #hypertension is important: https://t.co/zSJf5O6jS4 Learn more about RhythmScience's software & services for cardiac remote monitoring (HF/HTN/rhythm mangement): https://t.co/dYAqAnfZFO #remotecardiology #remotem
Study highlights importance of long-term management of hypertension https://t.co/QnteHKLA0a https://t.co/iZtQQTJUMJ https://t.co/g7sT10kmRU
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
RT @kaulcsmc: https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT…
https://t.co/e91PXvS3US Only reliable conclusion one can draw from this report is limited external generalizability of SPRINT. Lack of 'legacy effect' of BP lowering (reported previously) might also be supported. Calls for lowering BP targets based on thi
RT @cpgale3: Maintaining longer-term intensive blood pressure control in individuals aged 50 years & over with hypertension & high cardiova…
RT @cpgale3: Maintaining longer-term intensive blood pressure control in individuals aged 50 years & over with hypertension & high cardiova…
Maintaining longer-term intensive blood pressure control in individuals aged 50 years & over with hypertension & high cardiovascular risk without diabetes or stroke is difficult, & results in non-persisting treatment effects, outwith a trial.
RT @hanzou1121: SPRINT trialではsBP<120へのコントロールが中央値3.3年のフォローで心血管死をHR 0.66まで減少させたがその後のフォロー(中央値 8.8年)の二次解析で、血圧が平均で8mmHg上昇、心血管死 HR 1.02と効果がなくなって…
SPRINT trialではsBP<120へのコントロールが中央値3.3年のフォローで心血管死をHR 0.66まで減少させたがその後のフォロー(中央値 8.8年)の二次解析で、血圧が平均で8mmHg上昇、心血管死 HR 1.02と効果がなくなっていた。 https://t.co/oV1XDcBlBB
RT @hmkyale: My new @tiktok_us on blood pressure targets levels (what should they be); and what happens to patients in trials of lower bloo…
RT @hmkyale: My new @tiktok_us on blood pressure targets levels (what should they be); and what happens to patients in trials of lower bloo…
My new @tiktok_us on blood pressure targets levels (what should they be); and what happens to patients in trials of lower blood pressure targets when the trials end. https://t.co/gqe3KXcZTF @JAMACardio https://t.co/JqMuIQMw2d https://t.co/sOigmeZc2l
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
Mortality benefit of intensive BP diminished after SPRINT trail ended. SBP ⬆️ from 133 mmHg to about 140 mmHg ~5 after trial ended. Importance of sustained BP control cannot be ignored. We've come a long way since JNC8. #bloodpressure #CardioTwitter htt
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpatient systolic BP increased by an average of 7 mm Hg for participants in the intensive treatment group. #Research https://t.co/x2sOdX40
@lipo_fan Can you elaborate? https://t.co/898MtZnz5e
RT @3stars67664378: 📘血圧と心血管死亡 - RCT 9,361名 の2次解析 - SBP 120 vs 140 mmHgの比較 - 強化治療は心血管死亡 HR 0.66 (0.49-0.89) の有意な低下 - ただし長期的には血圧コントロールは悪化し、長…
📘血圧と心血管死亡 - RCT 9,361名 の2次解析 - SBP 120 vs 140 mmHgの比較 - 強化治療は心血管死亡 HR 0.66 (0.49-0.89) の有意な低下 - ただし長期的には血圧コントロールは悪化し、長期的な予後は改善せず 🏃🥦💊高血圧の長期的な管理が重要である可能性
【追加解析: SPRINT】心血管疾患リスク増加はあるが糖尿病や脳卒中の既往がない50歳以上の高血圧患者において、厳格な降圧は、標準的な降圧と比較して、総追跡期間中央値8.8年時点で心血管死亡や全原因死亡を減少させなかった。 #ペ読 https://t.co/6wUC8cq78f
RT @byronjaeger1: New article in JAMA Cardio! We investigated the long-term effect of reducing systolic BP to <120 mm Hg for ~3 years on CV…
Dr. Sohail showed us the results of a recently published secondary analysis of the SPRINT Trial. Check it out: https://t.co/PEHsScTHBc
Un traitement intensif contre l'#hypertension (systolique à 120 mmHg) n'est efficace (mortalité comprise) que pendant sa prescription. Tout revient à la direction initiale, quoique retardée. Adhésion, adhésion, comment te garder dans les clous ?🙄 https://t
RT @EstebanDL: Mantener la presión baja en el segumiento de los pacientes Una misión imposible hasta no entender ¿Qué nos pasa?, nos va a c…
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial - PubMed https://t.co/sH5duNozKa
RT @EstebanDL: Mantener la presión baja en el segumiento de los pacientes Una misión imposible hasta no entender ¿Qué nos pasa?, nos va a c…
"The beneficial effect of intensive treatment on cardiovascular and all-cause mortality did not persist after the SPRINT trial... These results highlight the importance of consistent long-term management of hypertension" https://t.co/buGKeClHxP
RT @EstebanDL: Mantener la presión baja en el segumiento de los pacientes Una misión imposible hasta no entender ¿Qué nos pasa?, nos va a c…
RT @EstebanDL: Mantener la presión baja en el segumiento de los pacientes Una misión imposible hasta no entender ¿Qué nos pasa?, nos va a c…
Mantener la presión baja en el segumiento de los pacientes Una misión imposible hasta no entender ¿Qué nos pasa?, nos va a costar tratar a nuestros pacientes Estamos llenos de teorías obsoletas y erradas, peleamos contra variables https://t.co/4EWyOXfkY4
RT @NammiKan: Benefits seen in a clinical trial erode after trial ends. More pragmatic trials focused on sustaining effects are needed.
RT @NHLBI_Translate: .#JAMA: @NIH_NHLBI-funded #SPRINT Trial: The beneficial effect of intensive treatment on CV and all-cause #mortality d…
.#JAMA: @NIH_NHLBI-funded #SPRINT Trial: The beneficial effect of intensive treatment on CV and all-cause #mortality did not persist after the trial. New findings highlight importance of consistent long-term control of #hypertension. #Outcome #ImpSci #HTN
RT @MondaEmanuele: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZy…
RT @MondaEmanuele: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZy…
RT @MondaEmanuele: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZy…
Sustaining BP control to the Systolic Blood Pressure Intervention Trial target of less than 120 mm Hg will be critical for achieving population reductions in cardiovascular mortality. | JAMA Cardiology https://t.co/hje1zoMPYo
RT @MondaEmanuele: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZy…
RT @MondaEmanuele: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZy…
RT @MondaEmanuele: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZy…
RT @MondaEmanuele: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZy…
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control @JAMACardio https://t.co/JZyLA4v6aV https://t.co/QJs0JKLXwa
Recent trial: Aggressive BP control to a Systolic Blood Pressure target of less than 120 mmHg is key for lowering death from cardiovascular causes https://t.co/YDA9KQLafX #hearthealth #Hypertension https://t.co/nOxLT7bcwK
RT @TGijonConde: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/MbrZFaxWUK vía @JAMA…
RT @TGijonConde: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/MbrZFaxWUK vía @JAMA…
RT @TGijonConde: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/MbrZFaxWUK vía @JAMA…
RT @TGijonConde: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/MbrZFaxWUK vía @JAMA…
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/MbrZFaxWUK vía @JAMACardio part of @JAMANetwork @SEHLELHA140_90 @AMAREVA_Madrid
RT @spjuraschek: Great paper using SPRINT follow-up data to show the need to maintain BP at goal long-term to prevent cardiovascular diseas…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @medical_xpress: Study highlights importance of long-term management of #hypertension @JAMACardio https://t.co/DETntDlMLl https://t.co/u…
RT @spjuraschek: Great paper using SPRINT follow-up data to show the need to maintain BP at goal long-term to prevent cardiovascular diseas…
Looking forward to discussing at tomorrow's journal club!
RT @spjuraschek: Great paper using SPRINT follow-up data to show the need to maintain BP at goal long-term to prevent cardiovascular diseas…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @spjuraschek: Great paper using SPRINT follow-up data to show the need to maintain BP at goal long-term to prevent cardiovascular diseas…
RT @jdmosqueral: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/ebOTIrVkgQ vía @JAMA…
RT @MWFriedberg: Mortality diff vanished in post-SPRINT follow-up https://t.co/QvjSDWMFhO 1. Could cessation of plausibly harmful “standard…
@AlexChaitoff @mikejohansenmd @JeremySussman @jlampre @spjuraschek @NMPajewski @JAMACardio Another hypothesis…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/ebOTIrVkgQ vía @JAMACardio part of @JAMANetwork
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
RT @JDodsonMD: Amen. Cc @DaichiShimbo @Aging_MD @MichaelJBlaha @mdmiedema @khurramn1 @ErinMichos @MichaelGNanna
RT @VCUDPOSChair: This provides further evidence that Systolic BP Time in Target Range could be a potential therapeutic target and quality…